NCT00629941

Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis

A Multi-Center, Open-Label Study Evaluating the Cytokine and Eyelid Margin Bacterial Load Levels of Subjects Diagnosed With Chronic Blepharitis Following Dosing With AzaSite® (Azithromycin Ophthalmic Solution) 1%

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs \& symptoms of blepharitis and tear cytokine and eyelid bacterial load levels

Conditions

• Blepharitis

Interventions

Type	Name	Description
DRUG	AzaSite®	Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days

Timeline

• Start date: 2008-03-01
• Primary completion: 2008-08-01
• First posted: 2008-03-06
• Last updated: 2011-09-26

Locations

2 sites across 1 country: United States